RegeneRx Reports Positive Results of Preclinical Dry Eye Study
02 11월 2010 - 8:30PM
Business Wire
RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (the
“Company” or “RegeneRx”) today announced the results of its first
non-clinical dry eye study using RGN-259, RegeneRx’s ophthalmic,
preservative-free eye drop for the treatment of Dry Eye Syndrome
(DES). In the study, animals were treated with RGN-259, a vehicle
control and a positive control, doxycycline. Corneal fluorescein
staining was used to measure the surface defects after induction of
DES using an industry accepted dry eye model. In animals treated
with RGN-259, a “dramatic” and statistically significant reduction
in corneal staining (p
Regenerx Biopharm In (AMEX:RGN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Regenerx Biopharm In (AMEX:RGN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Regenerx Biopharmaceuticals (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More RegeneRx Biopharmaceuticals, Inc. News Articles